Skip to main content
. Author manuscript; available in PMC: 2019 Feb 18.
Published in final edited form as: J Clin Lipidol. 2018 Oct 24;13(1):62–69. doi: 10.1016/j.jacl.2018.10.004

Figure 1.

Figure 1.

Assessing relative amounts of apo-CIII in the plasma by SDS-PAGE followed by western blotting with a goat polyclonal against human apo-CIII. The plasma levels of apo-CIII were higher on IFN β1a therapy (on) than after IFN β1a therapy was discontinued (off). A normolipidemic plasma sample (control) was also included as a control. A nonspecific band at ~50-kDa indicated that the loading of plasma samples was similar. IFN, interferon.